Literature DB >> 11056496

Pathology of benign prostatic hyperplasia.

C S Foster1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11056496     DOI： 10.1002/1097-0045(2000)45:9+<4::aid-pros3>3.0.co;2-q

Source DB:  PubMed          Journal:  Prostate Suppl        ISSN： 1050-5881


× No keyword cloud information.
  19 in total

1.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Jeannette M Schenk; Alan R Kristal; Marian L Neuhouser; Catherine M Tangen; Emily White; Daniel W Lin; Mario Kratz; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2010-02-08       Impact factor: 4.897

2.  Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.

Authors:  Qi-Peng Sun; Liao-Yuan Li; Zhong Chen; Jun Pang; Wei-Jiao Yang; Xiang-Fu Zhou; Jian-Guang Qiu; Zu-Lan Su; Dan He; Xin Gao
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

3.  Peripheral mononuclear leukocyte DNA damage, plasma prolidase activity, and oxidative status in patients with benign prostatic hyperplasia.

Authors:  Ilhan Gecit; Ismail Meral; Mehmet Aslan; Abdurrahim Kocyigit; Hakim Celik; Abdullah Taskın; Mehmet Kaba; Necip Pirincci; Mustafa Gunes; Kerem Taken; Halit Demir; Mehmet Uyuklu; Kadir Ceylan
Journal:  Redox Rep       Date:  2014-12-31       Impact factor: 4.412

4.  Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Authors:  Jeannette M Schenk; Alan R Kristal; Kathryn B Arnold; Catherine M Tangen; Marian L Neuhouser; Daniel W Lin; Emily White; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2011-05-03       Impact factor: 4.897

5.  Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.

Authors:  Michelle Yan; Karin Hardin; Emily Ho
Journal:  J Nutr Biochem       Date:  2009-07-02       Impact factor: 6.048

6.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

7.  Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?

Authors:  Jeannette M Schenk; Rachel Hunter-Merrill; Yingye Zheng; Ruth Etzioni; Roman Gulati; Catherine Tangen; Ian M Thompson; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2013-06-28       Impact factor: 4.897

8.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

9.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Authors:  G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.